^
    BIOMARKER:

    RANBP2-ALK rearrangement + TNFRSF8 expression

    i
    Other names: RANBP2, RAN Binding Protein 2, NUP358, Acute Necrotizing Encephalopathy 1 (Autosomal Dominant), Nuclear Pore Complex Protein Nup358, E3 SUMO-Protein Ligase RanBP2, Ran-Binding Protein 2, 358 KDa Nucleoporin, Nucleoporin Nup358, Nucleoporin 358, ADANE, P270, E3 SUMO-Protein Transferase RanBP2, Transformation-Related Protein 2, RanBP2, IIAE3, ANE1, TRP1, TRP2, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
    Entrez ID:
    238; 943; 5903
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others

    Associations

    Heatmap
    News
    Twitter
    Trials
    RANBP2-ALK rearrangement + TNFRSF8 expression
    Fibrosarcoma
    ceritinib + brentuximab vedotin
    Sensitive: D – Preclinical
    RANBP2-ALK rearrangement + TNFRSF8 expression
    Fibrosarcoma
    crizotinib + brentuximab vedotin
    Sensitive: D – Preclinical
    RANBP2-ALK rearrangement + TNFRSF8 expression
    Sarcoma
    brentuximab vedotin
    Resistant: D – Preclinical